Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q1 FY25 results · Apr–Jun 2024
Alivus Life Sciences reported revenue from operations of ₹588.62 crore (up 1.8% from Q1 FY24) and net profit of ₹111.48 crore (down 17.7% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a standalone basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 588.62 | 578.45 | +1.8% | 536.60 | +9.7% |
| Other income | 5.49 | 1.85 | +196.8% | 3.13 | +75.4% |
| Total income | 594.11 | 580.30 | +2.4% | 539.73 | +10.1% |
| Profit before tax | 150.24 | 182.00 | −17.5% | 129.68 | +15.9% |
| Net profit for the period | 111.48 | 135.45 | −17.7% | 97.94 | +13.8% |
| EPS, basic (₹) | 9.10 | 11.05 | −17.6% | 7.99 | +13.9% |
| Net margin (%) | 18.9 | 23.4 | 18.3 |
Standalone
- Filed with BSE
- 29 Jul 2024, 14:58 IST
- Board meeting
- 25 Jul 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE